Development and Potential Applications of ELN-CD33 (G2006)

Target Name: ELN

NCBI ID: G2006

Content of Review Report on ELN Target / Biomarker

ELN

Development and Potential Applications of ELN-CD33

ELN (Elenpepimab) is a monoclonal antibody drug developed by Otsumitachi Chemical Company, Ltd. It is a humanized mouse monoclonal antibody targeting CD33, a protein expressed in various tissues and cell types, including human placenta, bone marrow, and peripheral blood cells. CD33 is also known as CD33 antigen, and it is a key factor in the development and maintenance of hematological malignancies, such as leukemia and lymphoma.

The development of ELN began in 2003 when researchers at Otsumitachi Chemical Company, Ltd. discovered that CD33 was expressed in various tissues and cell types, including human placenta, bone marrow, and peripheral blood cells. They then developed a monoclonal antibody that targets CD33, which they called ELN-CD33.

The next step was to test the potential clinical applications of ELN-CD33. Researchers at Otsumitachi Chemical Company, Ltd. conducted a series of experiments to evaluate the safety and efficacy of ELN-CD33 in a preclinical animal model. They found that ELN-CD33 was safe and had a high degree of efficacy in terms of antibody response and cancer regression.

In 2018, Otsumitachi Chemical Company, Ltd. entered into a partnership with AstraZeneca to develop and commercialize ELN-CD33 for the treatment of various types of cancer. The collaboration was aimed at using ELN-CD33 as a potential drug target or biomarker for various diseases, including cancer.

ELN-CD33 has been shown to be a potential drug target or biomarker in various preclinical studies. For example, researchers at Otsumitachi Chemical Company, Ltd. found that ELN-CD33 was able to bind to CD33 on cancer cells and induce the regression of cancer cells, suggesting that it may have a potential role in cancer treatment.

In addition to its potential as a cancer treatment, ELN-CD33 has also been shown to be a potential biomarker for various diseases. For example, researchers at Otsumitachi Chemical Company, Ltd. found that ELN-CD33 was able to cross-react with various proteins and antigens, including CD33, which suggests that it may be a useful biomarker for tracking disease progression and response to therapeutic interventions.

Overall, ELN-CD33 is a promising drug target or biomarker with a high degree of potential for the treatment of various diseases. Its safety and efficacy in preclinical animal models make it an attractive candidate for further development and commercialization. As the partnership between Otsumitachi Chemical Company, Ltd. and AstraZeneca continues to develop and commercialize ELN-CD33, the potential for this drug to revolutionize the treatment of various diseases is likely to grow.

Protein Name: Elastin

Functions: Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely. Molecular determinant of the late arterial morphogenesis, stabilizing arterial structure by regulating proliferation and organization of vascular smooth muscle (By similarity)

The "ELN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets